أعرض في EDS

Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice

التفاصيل البيبلوغرافية
العنوان: Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice
المؤلفون: Seng Gee Lim, Joseph Hoang, Tomonori Senoo, Hansen Dang, Daniel Q. Huang, Nicholas Chien, Ramsey Cheung, Hidenori Toyoda, Satoshi Yasuda, Joanne Liu, Linda Henry, Huy N. Trinh, Mindie H. Nguyen, Sabrina Quek, Taeang Arai, Jennifer Leong, Keisuke Yokohama, Sally Tran, Makoto Chuma, Koichi Takaguchi, Tsunamasa Watanabe, Masanori Atsukawa, Haruki Uojima, Richard H. Le, Mayumi Maeda, Akira Asai, Toru Ishikawa, Khin Naing Thin, Shinya Fukunishi, Charles S. Landis
المصدر: Hepatology (Baltimore, Md.)References. 74(2)
سنة النشر: 2021
مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Hepatitis B virus, Cirrhosis, Tenofovir, Population, Urology, Renal function, Kidney, Tenofovir alafenamide, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Hepatitis B, Chronic, Liver Function Tests, Diabetes mellitus, medicine, Humans, Prodrugs, Stage (cooking), Renal Insufficiency, Chronic, education, Aged, Retrospective Studies, education.field_of_study, Alanine, Hepatology, business.industry, Drug Substitution, Alanine Transaminase, Middle Aged, medicine.disease, 030104 developmental biology, Liver, DNA, Viral, 030211 gastroenterology & hepatology, Female, business, Kidney disease, medicine.drug, Glomerular Filtration Rate
الوصف: BACKGROUND AND AIMS Real-world data for treatment effectiveness and renal outcomes in chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) are limited. Therefore, we aimed to evaluate treatment and renal outcomes of this population. APPROACH AND RESULTS We analyzed 834 patients with CHB previously treated with TDF for ≥12 months who were switched to TAF in routine practice at 13 US and Asian centers for changes in viral (HBV DNA 0.44) or mean eGFR (P > 0.83, adjusted for age, sex, baseline eGFR, and diabetes, hypertension, or cirrhosis by generalized linear modeling) remained stable. However, among those with baseline eGFR
تدمد: 1527-3350
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40153d31cf1380ccf5bb51fc751801e1
https://pubmed.ncbi.nlm.nih.gov/33706421
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....40153d31cf1380ccf5bb51fc751801e1
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15273350